Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Seattle, Astellas bag speedy FDA okay for bladder cancer drug the label, including Roche’s Tecentriq (atezolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

FDA panel clears Keytruda for hard-to-treat bladder cancer

FDA panel clears Keytruda for hard-to-treat bladder cancer Tecentriq (atezolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC

AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC Meantime, Bristol-Myers Squibb also has a phase 2 trial in this setting with its PD-1 inhibitor Opdivo (nivolumab) – also approved for third-line use in SCLC. ... BMS tested Opdivo with its already-approved TLA4 inhibitor Yervoy (ipilimumab) as a

China updates drug reimbursement list, agrees price cuts

China updates drug reimbursement list, agrees price cuts It is the first and only PD-1 inhibitor to be included on the NRDL – Merck’s Keytruda (pembrolizumab) and BMS’ Opdivo (nivolumab) are not present on the updated list. ... However, BMS’ Opdivo claimed the first PD-1 approval in China, when it was

Merck’s Keytruda significantly extends life in some prostate cancer patients

Merck’s Keytruda significantly extends life in some prostate cancer patients Merck has competition in the area however, with rival from Bristol-Myers Squibb garnering positive results with its double immunotherapy combination PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab)

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics